Setting a new standard for transplant patients
The cobas® EBV test provides reliable, standardised, high-quality results for clinical decision-making and for the improved management of transplant patients at risk of infection. The test is used by healthcare professionals to assess if transplant patients are at risk of developing disease caused by EBV, which can contribute to organ rejection. The test is for use on the automated cobas® 6800/8800 Systems in countries accepting the CE mark.
Features and benefits of the cobas® EBV test
- Standardisation – Results traceable to the WHO International Standard and reporting in IU/mL for improved harmonisation in testing results across hospitals and institutions
- State-of-the-art design – Best-in-class performance with dual target assay designs to provide reliable and reproducible results for reassurance in clinical decision making
- Efficiency, flexibility and simplicity – Ability to perform critical transplant testing (CMV, EBV, BKV) from a single sample on the cobas® 6800/8800 Systems with an industry-leading menu, for proven performance and allowing for absolute automation
EBV could cause transplant-transmitted infections in immunocompromised transplant patients and is associated with a range of cancers, such as post-transplant lymphoproliferative disorder (PTLD).1 Early intervention with best-in-class monitoring tools provides actionable results which enable informed treatment decisions.